Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study

Clinical Pharmacokinetics

Volumn 55, Issue 3, 2016, Pages 359-367

  Alexopoulos, Dimitrios ^a   Barampoutis, Nikolaos ^a   Gkizas, Vasileios ^a   Vogiatzi, Chrysoula ^a   Tsigkas, Grigorios ^a   Koutsogiannis, Nikolaos ^a   Davlouros, Periklis ^a   Hahalis, George ^a   Nylander, Sven ^b   Parodi, Guido ^c   Xanthopoulou, Ioanna ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b ASTRAZENECA R AND D   (Sweden)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; TABLET;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CRUSHED TABLET; DRUG DOSAGE FORM COMPARISON; DRUG MECHANISM; FEMALE; HUMAN; INTEGRAL TABLET; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLASMA CONCENTRATION-TIME CURVE; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STANDING; TABLET; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; AGED; ANALOGS AND DERIVATIVES; BLOOD; BODY POSTURE; METABOLISM; MYOCARDIAL INFARCTION; SINGLE BLIND PROCEDURE;

ADENOSINE; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; POSTURE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; SINGLE-BLIND METHOD; TABLETS;

EID: 84959134908     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0320-0     Document Type: Article

References (26)

1. Alexopoulos D, Xanthopoulou I, Goudevenos J. Effects of P2Y12 receptor inhibition in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2014;113:2064–9.
2. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–619.
3. American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions, O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:e78–140.
4. Heestermans AA, van Werkum JW, Taubert D, Seesing TH, von Beckerath N, Hackeng CM, et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res. 2008;122:776–81.
5. Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, et al. FABOLUS PRO Investigators. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. J Am Coll Cardiol Interv. 2012;5:268–77.
6. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST elevation myocardial infarction. Circ Cardiovasc Interv. 2012;5:797–804.
7. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI study. J Am Coll Cardiol. 2013;61:1601–6.
8. Alexopoulos D, Gkizas V, Patsilinakos S, Xanthopoulou I, Angelidis C, Anthopoulos P, et al. Double versus standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI. J Am Coll Cardiol. 2013;62:940–1.
9. Parodi G, Bellandi B, Valenti R, Migliorini A, Marcucci R, Carrabba N, et al. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study. Am Heart J. 2014;167:909–14.
10. Alexopoulos D, Makris G, Xanthopoulou I, Patsilinakos S, Deftereos S, Gkizas V, et al. Onset of antiplatelet action with high (100 mg) versus standard (60 mg) loading dose of prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: pharmacodynamic study. Circ Cardiovasc Interv. 2014;7:233–9.
11. Parodi G, Xanthopoulou I, Bellandi B, Gkizas V, Valenti R, Karanikas S, et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol. 2015;10(65):511–2.
12. Zhang X, Xiang X, Tu L, Xie X, Hou X. Esophageal motility in the supine and upright positions for liquid and solid swallows through high-resolution manometry. J Neurogastroenterol Motil. 2013;19:467–72.
13. Crean B, Finnie C, Crosby A. Evaluation of crushed ticagrelor tablet doses: recovery following crushing and naso-gastric tube passage ex vivo. Drugs. 2013;13:153–7.
14. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al. Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261–73.
15. Sillén H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2010;878:2299–306.
16. Husted SE, Storey RF, Bliden K, Tantry US, Høimark L, Butler K, et al. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET–OFFSET and RESPOND studies. Clin Pharmacokinet. 2012;51:397–409.
17. Zafar MU, Farkouh ME, Fuster V, Chesebro JH. Crushed clopidogrel administered via nasogastric tube has faster and greater absorption than oral whole tablets. J Interv Cardiol. 2009;22:385–9.
18. Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50:1852–6.
19. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577–85.
20. Teng R, Carlson G, Hsia J. An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. Int J Clin Pharmacol Ther. 2015;53:183–9.
21. Montalescot G, van’t Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, et al. ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371:1016–27.
22. Parodi G, Alexopoulos D. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371:2337–8.
23. 12 receptor antagonist. J Clin Pharmacol. 2010;50:27–35.
24. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368:1303–13.
25. Parodi G, Bellandi B, Xanthopoulou I, Capranzano P, Capodanno D, Valenti R, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2014;8(1):e001593. doi:10.1161/CIRCINTERVENTIONS.114.001593.
26. Alexopoulos D. OraL crushed and dIspersed ticagrelor 180mg compared to whole tablets of eQUal dose in STEMI patients unDergoing primary PCI: a pharmacokinetic/pharmacodynamic study (the LIQUID Study) [ClinicalTrials.gov identifier NCT02046486]. US National Institutes of Health, ClinicalTrials.gov. https://www.clinicaltrials.gov. Accessed 6 Aug 2015.